Dr
GSK, United Kingdom
I joined GSK in 2006 and have worked on multiple hit-to-lead and lead optimisation projects in respiratory, immuno-inflammation and cancer. I have been working in the targeted protein degradation field since 2012, where I am a Team leader, with experience leading projects in discovery and lead optimisation of PROTACs and E3 ligases. More recently, I have collaborated with GSK's Discovery high throughput chemistry (DHTC) group, to develop an integrated biology and chemical screening platform (D2B) for the synthesis of PROTACs. This is now routinely used by all PROTAC projects in an HTC fashion and has had significant impact on reducing cycle times.
My research interests include new modalities in protein degradation such as molecular glues, novel E3 Ligases and the ubiquitin proteasome system.
Wednesday, May 24, 2023
12:00 – 12:30 CET